Rosen Law Firm Urges AstraZeneca PLC Investors to Act Before Deadline in Securities Class Action

NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) --

Overview: The Rosen Law Firm, a respected global firm specializing in investor rights, has issued a reminder for individuals who purchased securities of AstraZeneca PLC (NASDAQ: AZN) within the period from February 23, 2022, to December 17, 2024. This is known as the "Class Period." Investors have until February 21, 2025, to secure their involvement as lead plaintiffs in a class action lawsuit that the firm has initiated.

Significance: If you are among those who bought AstraZeneca securities during the Class Period, you may be eligible for compensation without having to pay any upfront fees or costs, thanks to a contingency fee arrangement.

Next Steps: To participate in the AstraZeneca class action lawsuit, you can visit this link, call attorney Phillip Kim at 866-767-3653, or contact him via email at [email protected]. Note that a class action lawsuit has already been filed. If you wish to be appointed as the lead plaintiff, you must file a motion with the court by February 21, 2025. A lead plaintiff acts on behalf of other investors in directing the case’s proceedings.

Why Choose Rosen Law Firm: It is crucial for investors to select a law firm that has a proven record of success in handling securities class actions. Many firms that send out notices may lack the necessary experience, resources, or recognition in the field. A good number of these firms do not actually prosecute securities class actions but act merely as intermediaries, referring clients to other firms that do the work. The Rosen Law Firm has successfully represented investors globally, focusing on securities class actions and shareholder derivative lawsuits. The firm made headlines for achieving the largest securities class action settlement against a Chinese company at a time, and consistently ranks high in settlements among class action firms. In 2019 alone, Rosen Law Firm recovered over $438 million for its clients, and its founding partner Laurence Rosen earned recognition as a leading figure in representing plaintiffs.

Case Details: The lawsuit alleges that during the Class Period, AstraZeneca’s executives made materially false statements and omissions, such as: (1) the company engaged in fraudulent insurance practices in China; (2) this led to increased legal risks for AstraZeneca, culminating in the detention of its China President; (3) AstraZeneca downplayed its legal liabilities; and (4) revelations about these issues could significantly damage AstraZeneca's operations in China. Investors faced losses when the true state of affairs became known.

For more information on joining the class action, visit this link, call Phillip Kim at 866-767-3653, or email [email protected]. Please be aware that no class has been officially certified yet. Until then, investors are not represented unless they hire a lawyer.

Follow the Rosen Law Firm for updates on LinkedIn or Twitter.

Attorney Advertising. Previous results do not guarantee similar outcomes.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

AstraZeneca, lawsuit, investment